

India GLP-1 Receptor Agonist Market Size, Share & Trends Analysis Report By Product (Semaglutide, Tirzepatide, Dulaglutide), By Application (Type 2 Diabetes Mellitus, Cardiovascular Risk), By Route Of Administration, By Distribution Channel, And Segment Forecasts, 2026 - 2033

<https://marketpublishers.com/r/IF7AAA3A585AEN.html>

Date: June 2026

Pages: 150

Price: US\$ 5,950.00 (Single User License)

ID: IF7AAA3A585AEN

Abstracts

The India GLP-1 receptor agonist market size was valued at USD 150.8 million in 2025 and is projected to grow from USD 240.5 million in 2026 to USD 1,004.9 million by 2033, at a CAGR of 22.7% from 2026 to 2033. The market is witnessing strong expansion, driven by the rising prevalence of type 2 diabetes and obesity, alongside increasing clinical adoption of advanced incretin-based therapies. Semaglutide and dulaglutide remain the most widely prescribed molecules, supported by established efficacy in glycemic control and weight reduction benefits.

Urban healthcare centers and endocrinology-led clinics account for the majority of prescriptions, as awareness of metabolic disease management improves across Tier 1 and Tier 2 cities. Building on this expanding demand base, competitive dynamics in the India GLP-1 market are intensifying with the presence of both multinational innovators and domestic pharmaceutical companies. Novo Nordisk and Eli Lilly maintain a strong position through semaglutide and tirzepatide offerings, particularly in premium urban segments. At the same time, Indian companies such as Sun Pharma, Dr. Reddy's Laboratories, Cipla, and Biocon are actively strengthening their presence through biosimilar development and anticipated post-patent entry strategies. This competitive environment is expected to significantly reshape pricing structures, especially as semaglutide patent protections approach expiry in India.

The India GLP-1 receptor agonist market is expected to transition toward broader accessibility and volume-driven growth, particularly in the post-patent period. Tirzepatide is emerging as a key growth driver due to its dual GIP and GLP-1 mechanism, offering enhanced weight-loss outcomes compared to traditional therapies. Meanwhile, expanding awareness of obesity as a chronic disease is gradually increasing uptake beyond diabetes-focused treatment, particularly in urban private-pay segments. Price reductions anticipated from generic semaglutide entries are expected to further accelerate market penetration across Tier 2 and Tier 3 cities. Overall, the market is evolving from a specialist-driven niche therapy space into a more mainstream metabolic treatment category, supported by stronger physician adoption, improving affordability, and widening patient eligibility across India's healthcare system.

India GLP-1 Receptor Agonist Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the India GLP-1 receptor agonist market report based on product, application, route of administration, and distribution channel:

Product Outlook (Revenue, USD Million, 2021 - 2033)

Semaglutide (Ozempic, Wegovy, Rybelsus)

Tirzepatide (Mounjaro, Zepbound)

Dulaglutide (Trulicity)

Liraglutide (Victoza, Saxenda)

Others (Byetta, Bydureon, SOLIQUA)

Application Outlook (Revenue, USD Million, 2021 - 2033)

Type 2 Diabetes Mellitus

Obesity / Chronic Weight Management

Cardiovascular Risk

Route of Administration Outlook(Revenue, USD Million, 2021 - 2033)

Injectable / Parenteral

Oral

Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Contents

CHAPTER 1. METHODOLOGY AND SCOPE

- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
 - 1.2.1. Product
 - 1.2.2. Application
 - 1.2.3. Route of Administration
 - 1.2.4. Distribution Channel
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
 - 1.5.1. Purchased Database
 - 1.5.2. GVR's Internal Database
 - 1.5.3. Secondary Sources
 - 1.5.4. Primary Research
- 1.6. Information Analysis
 - 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
 - 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives

CHAPTER 2. EXECUTIVE SUMMARY

- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot

CHAPTER 3. INDIA GLP-1 RECEPTOR AGONIST MARKET VARIABLES, TRENDS, & SCOPE

- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
 - 3.2.1. Market Driver Analysis
 - 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis

3.3.1. Industry Analysis - Porter's Five Forces Analysis

3.3.1.1. Supplier Power

3.3.1.2. Buyer Power

3.3.1.3. Substitution Threat

3.3.1.4. Threat of New Entrants

3.3.1.5. Competitive Rivalry

3.3.2. PESTLE Analysis

3.3.3. Pipeline Analysis

3.3.4. Patent Expiry Analysis

3.3.5. Pricing Analysis

CHAPTER 4. INDIA GLP-1 RECEPTOR AGONIST MARKET: PRODUCT BUSINESS ANALYSIS

4.1. Product Market Share, 2025 & 2033

4.2. Product Segment Dashboard

4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)

4.4. Semaglutide (Ozempic, Wegovy, Rybelsus)

4.4.1. Semaglutide (Ozempic, Wegovy, Rybelsus) Market, 2021 - 2033 (USD Million)

4.5. Tirzepatide (Mounjaro, Zepbound)

4.5.1. Tirzepatide (Mounjaro, Zepbound) Market, 2021 - 2033 (USD Million)

4.6. Dulaglutide (Trulicity)

4.6.1. Dulaglutide (Trulicity) Market, 2021 - 2033 (USD Million)

4.7. Liraglutide (Victoza, Saxenda)

4.7.1. Liraglutide (Victoza, Saxenda) Market, 2021 - 2033 (USD Million)

4.8. Others (Byetta, Bydureon, SOLIQUA)

4.8.1. Others (Byetta, Bydureon, SOLIQUA) Market, 2021 - 2033 (USD Million)

CHAPTER 5. INDIA GLP-1 RECEPTOR AGONIST MARKET: APPLICATION BUSINESS ANALYSIS

5.1. Application Market Share, 2025 & 2033

5.2. Application Segment Dashboard

5.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)

5.4. Type 2 Diabetes Mellitus

5.4.1. Type 2 Diabetes Mellitus Market, 2021 - 2033 (USD Million)

5.5. Obesity / Chronic Weight Management

- 5.5.1. Obesity / Chronic Weight Management Market, 2021 - 2033 (USD Million)
- 5.6. Cardiovascular Risk
 - 5.6.1. Cardiovascular Risk Market, 2021 - 2033 (USD Million)

CHAPTER 6. INDIA GLP-1 RECEPTOR AGONIST MARKET: ROUTE OF ADMINISTRATION BUSINESS ANALYSIS

- 6.1. Route of Administration Market Share, 2025 & 2033
- 6.2. Route of Administration Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Million)
- 6.4. Injectable / Parenteral
 - 6.4.1. Injectable / Parenteral Market, 2021 - 2033 (USD Million)
- 6.5. Oral
 - 6.5.1. Oral Market, 2021 - 2033 (USD Million)

CHAPTER 7. INDIA GLP-1 RECEPTOR AGONIST MARKET: DISTRIBUTION CHANNEL BUSINESS ANALYSIS

- 7.1. Distribution Channel Market Share, 2025 & 2033
- 7.2. Distribution Channel Segment Dashboard
- 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
- 7.4. Hospital Pharmacies
 - 7.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
- 7.5. Retail Pharmacies
 - 7.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
- 7.6. Online Pharmacies
 - 7.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)

CHAPTER 8. COMPETITIVE LANDSCAPE

- 8.1. Participant Overview
- 8.2. Company Market Position Analysis
- 8.3. Company Categorization
- 8.4. Strategy Mapping
- 8.5. Company Profiles/Listing
 - 8.5.1. Novo Nordisk A/S
 - 8.5.1.1. Overview

- 8.5.1.2. Financial Performance
- 8.5.1.3. Product Benchmarking
- 8.5.1.4. Strategic Initiatives
- 8.5.2. Eli Lilly and Company
 - 8.5.2.1. Overview
 - 8.5.2.2. Financial Performance
 - 8.5.2.3. Product Benchmarking
 - 8.5.2.4. Strategic Initiatives
- 8.5.3. Sun Pharmaceutical Industries Ltd
 - 8.5.3.1. Overview
 - 8.5.3.2. Financial Performance
 - 8.5.3.3. Product Benchmarking
 - 8.5.3.4. Strategic Initiatives
- 8.5.4. Dr. Reddy's Laboratories Ltd
 - 8.5.4.1. Overview
 - 8.5.4.2. Financial Performance
 - 8.5.4.3. Product Benchmarking
 - 8.5.4.4. Strategic Initiatives
- 8.5.5. Zydus Lifesciences
 - 8.5.5.1. Overview
 - 8.5.5.2. Financial Performance
 - 8.5.5.3. Product Benchmarking
 - 8.5.5.4. Strategic Initiatives
- 8.5.6. Lupin Limited
 - 8.5.6.1. Overview
 - 8.5.6.2. Financial Performance
 - 8.5.6.3. Product Benchmarking
 - 8.5.6.4. Strategic Initiatives
- 8.5.7. Torrent Pharmaceuticals Ltd
 - 8.5.7.1. Overview
 - 8.5.7.2. Financial Performance
 - 8.5.7.3. Product Benchmarking
 - 8.5.7.4. Strategic Initiatives
- 8.5.8. Cipla
 - 8.5.8.1. Overview
 - 8.5.8.2. Financial Performance
 - 8.5.8.3. Product Benchmarking
 - 8.5.8.4. Strategic Initiatives
- 8.5.9. Emcure Pharmaceuticals Ltd

- 8.5.9.1. Overview
- 8.5.9.2. Financial Performance
- 8.5.9.3. Product Benchmarking
- 8.5.9.4. Strategic Initiatives
- 8.5.10. Abbott Laboratories
 - 8.5.10.1. Overview
 - 8.5.10.2. Financial Performance
 - 8.5.10.3. Product Benchmarking
 - 8.5.10.4. Strategic Initiatives?

List Of Tables

LIST OF TABLES

Table 1 List of secondary sources

Table 2 List of abbreviations

Table 3 India GLP-1 receptor agonist market, by product, 2021 - 2033 (USD Million)

Table 4 India GLP-1 receptor agonist market, by application, 2021 - 2033 (USD Million)

Table 5 India GLP-1 receptor agonist market, by route of administration, 2021 - 2033 (USD Million)

Table 6 India GLP-1 receptor agonist market, by distribution channel, 2021 - 2033 (USD Million)?

List Of Figures

LIST OF FIGURES

- Fig. 1 India GLP-1 receptor agonist market segmentation
- Fig. 2 Market research process
- Fig. 3 Data triangulation techniques
- Fig. 4 Primary research pattern
- Fig. 5 Market research approaches
- Fig. 6 Value-chain-based sizing & forecasting
- Fig. 7 Market formulation & validation
- Fig. 8 Market snapshot
- Fig. 9 Competitive landscape
- Fig. 10 India GLP-1 receptor agonist market dynamics
- Fig. 11 India GLP-1 receptor agonist market: Porter's five forces analysis
- Fig. 12 India GLP-1 receptor agonist market: PESTLE analysis
- Fig. 13 Product market, 2021 - 2033 (USD Million)
- Fig. 14 Semaglutide (Ozempic, Wegovy, Rybelsus) market, 2021 - 2033 (USD Million)
- Fig. 15 Tirzepatide (Mounjaro, Zepbound) market, 2021 - 2033 (USD Million)
- Fig. 16 Dulaglutide (Trulicity) market, 2021 - 2033 (USD Million)
- Fig. 17 Liraglutide (Victoza, Saxenda) market, 2021 - 2033 (USD Million)
- Fig. 18 Others (Byetta, Bydureon, SOLIQUA) market, 2021 - 2033 (USD Million)
- Fig. 19 Application market, 2021 - 2033 (USD Million)
- Fig. 20 Type 2 diabetes mellitus market, 2021 - 2033 (USD Million)
- Fig. 21 Obesity / Chronic Weight Management market, 2021 - 2033 (USD Million)
- Fig. 22 Cardiovascular Risk market, 2021 - 2033 (USD Million)
- Fig. 23 Route of administration market, 2021 - 2033 (USD Million)
- Fig. 24 Injectable / Parenteral market, 2021 - 2033 (USD Million)
- Fig. 25 Oral market, 2021 - 2033 (USD Million)
- Fig. 26 Distribution channel market, 2021 - 2033 (USD Million)
- Fig. 27 Hospital pharmacies market, 2021 - 2033 (USD Million)
- Fig. 28 Retail pharmacies market, 2021 - 2033 (USD Million)
- Fig. 29 Online pharmacies market, 2021 - 2033 (USD Million)
- Fig. 30 India GLP-1 receptor agonist market, 2018 - 2030 (USD Million)
- Fig. 31 Company categorization
- Fig. 32 Company market position analysis
- Fig. 33 Strategic framework

I would like to order

Product name: India GLP-1 Receptor Agonist Market Size, Share & Trends Analysis Report By Product (Semaglutide, Tirzepatide, Dulaglutide), By Application (Type 2 Diabetes Mellitus, Cardiovascular Risk), By Route Of Administration, By Distribution Channel, And Segment Forecasts, 2026 - 2033

Product link: <https://marketpublishers.com/r/IF7AAA3A585AEN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/IF7AAA3A585AEN.html>